Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study

NCT07026604 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Cavernous Malformation, Cerebral

Interventions

DRUG: Daratumumab

Sponsor

Beijing Tiantan Hospital